<DOC>
	<DOCNO>NCT00398320</DOCNO>
	<brief_summary>Given lack viable treatment option metastatic neuroendocrine tumor , contrast positive anecdotal experience , relative tolerability treatment regimen colorectal cancer patient , propose single-institution phase II trial investigate efficacy capecitabine , oxaliplatin bevacizumab patient metastatic neuroendocrine tumor .</brief_summary>
	<brief_title>Phase II Capecitabine , Oxaliplatin &amp; Bevacizumab Metastatic / Unresectable Neuroendocrine Tumors</brief_title>
	<detailed_description>PRIMARY 1 . Determine estimation median time progression ( TTP ) patient treat bevacizumab combination capecitabine oxaliplatin 2 . Assess toxicity associate regimen SECONDARY 1 . Determine objective response rate ( RR ) patient treat regimen 2 . Conduct exploratory analysis efficacy accord degree tumor differentiation primary location 3 . Determine utility biochemical marker surrogate endpoint tumor response</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Subjects must treat Stanford University Medical Center entire length study participation . Patients must histologically cytologically confirm neuroendocrine tumor , include welldifferentiated tumor ( carcinoid ) moderately poorly differentiate tumor . Patients must deem unresectable due involvement critical vasculature , adjacent organ invasion , presence metastasis . Patients prior surgical resection develop radiological clinical evidence metastatic cancer require separate histological cytological confirmation metastatic disease unless interval &gt; 5 year elapse primary surgery development metastatic disease . Clinicians consider biopsy lesion establish diagnosis metastatic disease substantial clinical ambiguity regard nature source apparent metastasis . Prior chemotherapy permit , although patient may prior oxaliplatin . Patients must primary metastatic lesion measurable least one dimension Modified RECIST criterion ( see Section 4.2 ) within 4 week prior entry study Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Patients must ≥ 18 year age Laboratory value ≤ 2 week prior randomization : Absolute Neutrophil Count ( ANC ) &gt; =1500/mm3 Platelets ( PLT ) ≥ 100,000/mm3 Hemoglobin ( Hgb ) ≥ 9 g/dL Serum creatinine ≤ 1.5 x upper limit normal ( ULN ) Serum bilirubin ≤ 1.5 x ULN ( ≤ 3.0 x ULN liver metastasis present ) Aspartate aminotransferase ( AST/SGOT ) , alanine aminotransferase ( ALT/SGPT ) , alkaline phosphatase ≤ 3.0 x ULN ( ≤ 5.0 x ULN liver metastasis present ) . Note : Endoscopic retrograde cholangiopancreatogram ( ERCP ) percutaneous stenting may use normalize liver function test . Life expectancy ≥ 12 week Ability give write informed consent accord local guideline DiseaseSpecific Exclusions 1 . Prior oxaliplatin reason . 2 . Prior full field radiotherapy ≤ 4 week limited field radiotherapy ≤ 2 week prior enrollment . Patients must recover therapyrelated toxicity . The site previous radiotherapy evidence progressive disease site disease . 3 . Prior biologic immunotherapy ≤ 2 week prior registration . Patients must recover therapyrelated toxicity 4 . Prior therapy antivascular endothelial growth factor ( VEGF ) agents 5 . If history primary cancer , subject eligible : Curatively resect nonmelanomatous skin cancer Curatively treat cervical carcinoma situ Other primary solid tumor curatively treat know active disease present treatment administer last 3 year 6 . Concurrent use investigational agent patient receive investigational drug ≤ 4 week prior enrollment . General Medical Exclusions 1 . Subjects know chronic active hepatitis B C infection 2 . History medical psychiatric condition laboratory abnormality opinion investigator may increase risk associate study participation study drug administration may interfere conduct study interpretation study result 3 . Male subject willing use adequate contraception upon enrollment study 6 month follow last dose secondline treatment 4 . Female subject ( childbearing potential , postmenopausal le 6 month , surgically sterilize , abstinent ) willing use oral , patch implant contraceptive , doublebarrier birth control , intrauterine device ( IUD ) course study 6 month follow last dose secondline treatment 5 . Female subject breastfeed positive serum pregnancy test 72 hour prior randomization 6 . Pleural effusion ascites cause respiratory compromise ( ≥ CTCAE grade 2 dyspnea ) 7 . Any following concurrent severe and/or uncontrolled medical condition within 24 week enrollment could compromise participation study : Unstable angina pectoris Symptomatic congestive heart failure Myocardial infarction ≤ 6 month prior registration and/or randomization Serious uncontrolled cardiac arrhythmia Uncontrolled diabetes Active uncontrolled infection Interstitial pneumonia extensive symptomatic interstitial fibrosis lung Chronic renal disease Acute chronic liver disease ( eg , hepatitis , cirrhosis ) 8 . Patients unwilling unable comply protocol 9 . Life expectancy le 12 week 10 . Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study Genentechsponsored bevacizumab cancer study BevacizumabSpecific Exclusions 1 . Inadequately control hypertension ( define systolic blood pressure &gt; 150 and/or diastolic blood pressure &gt; 100 mmHg antihypertensive medication ) 2 . Any prior history hypertensive crisis hypertensive encephalopathy 3 . New York Heart Association ( NYHA ) Grade II great congestive heart failure ( see Appendix E ) 4 . History myocardial infarction unstable angina within 6 month prior study enrollment 5 . History stroke transient ischemic attack within 6 month prior study enrollment 6 . Known central nervous system ( CNS ) disease 7 . Significant vascular disease ( eg , aortic aneurysm , aortic dissection ) 8 . Symptomatic peripheral vascular disease 9 . Evidence bleed diathesis coagulopathy 10 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study enrollment anticipation need major surgical procedure course study 11 . Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior study enrollment 12 . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior study enrollment 13 . Serious , nonhealing wound , ulcer , bone fracture 14 . Urine protein ≥ 2+ urinalysis dipstick ≥ 1.0 gram 24hour urine collection 15 . Known hypersensitivity component bevacizumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>